vs
Amplitude, Inc.（AMPL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Amplitude, Inc.的1.4倍（$127.1M vs $91.4M），再鼎医药同比增速更快（17.1% vs 17.0%），Amplitude, Inc.自由现金流更多（$12.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.2%）
Amplitude是一家美国企业，专注于研发数字分析软件，能够帮助企业梳理用户行为数据、优化产品决策与数字化运营体验。该公司于2021年9月28日在纳斯达克交易所挂牌上市，股票代码为AMPL。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AMPL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$91.4M
营收增速更快
ZLAB
高出0.1%
17.0%
自由现金流更多
AMPL
多$39.3M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $91.4M | $127.1M |
| 净利润 | $-17.7M | — |
| 毛利率 | 74.6% | 51.0% |
| 营业利润率 | -18.3% | -54.6% |
| 净利率 | -19.3% | — |
| 营收同比 | 17.0% | 17.1% |
| 净利润同比 | 45.8% | — |
| 每股收益（稀释后） | $-0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPLZLAB
| Q4 25 | $91.4M | $127.1M | ||
| Q3 25 | $88.6M | $115.4M | ||
| Q2 25 | $83.3M | $109.1M | ||
| Q1 25 | $80.0M | $105.7M | ||
| Q4 24 | $78.1M | $108.5M | ||
| Q3 24 | $75.2M | $101.8M | ||
| Q2 24 | $73.3M | $100.1M | ||
| Q1 24 | $72.6M | $87.1M |
净利润AMPLZLAB
| Q4 25 | $-17.7M | — | ||
| Q3 25 | $-24.0M | $-36.0M | ||
| Q2 25 | $-24.7M | $-40.7M | ||
| Q1 25 | $-22.2M | $-48.4M | ||
| Q4 24 | $-32.6M | — | ||
| Q3 24 | $-16.9M | $-41.7M | ||
| Q2 24 | $-23.4M | $-80.3M | ||
| Q1 24 | $-21.5M | $-53.5M |
毛利率AMPLZLAB
| Q4 25 | 74.6% | 51.0% | ||
| Q3 25 | 73.9% | 59.5% | ||
| Q2 25 | 72.6% | 60.6% | ||
| Q1 25 | 74.7% | 63.6% | ||
| Q4 24 | 74.7% | 61.5% | ||
| Q3 24 | 75.1% | 64.1% | ||
| Q2 24 | 73.4% | 64.9% | ||
| Q1 24 | 74.0% | 61.4% |
营业利润率AMPLZLAB
| Q4 25 | -18.3% | -54.6% | ||
| Q3 25 | -26.0% | -42.3% | ||
| Q2 25 | -29.0% | -50.3% | ||
| Q1 25 | -26.8% | -53.3% | ||
| Q4 24 | -41.2% | -62.6% | ||
| Q3 24 | -21.4% | -66.6% | ||
| Q2 24 | -31.7% | -76.0% | ||
| Q1 24 | -29.0% | -80.7% |
净利率AMPLZLAB
| Q4 25 | -19.3% | — | ||
| Q3 25 | -27.1% | -31.2% | ||
| Q2 25 | -29.6% | -37.3% | ||
| Q1 25 | -27.8% | -45.8% | ||
| Q4 24 | -41.7% | — | ||
| Q3 24 | -22.4% | -40.9% | ||
| Q2 24 | -31.9% | -80.2% | ||
| Q1 24 | -29.5% | -61.4% |
每股收益（稀释后）AMPLZLAB
| Q4 25 | $-0.13 | $-0.05 | ||
| Q3 25 | $-0.18 | $-0.03 | ||
| Q2 25 | $-0.19 | $-0.04 | ||
| Q1 25 | $-0.17 | $-0.04 | ||
| Q4 24 | $-0.25 | $-0.09 | ||
| Q3 24 | $-0.14 | $-0.04 | ||
| Q2 24 | $-0.19 | $-0.08 | ||
| Q1 24 | $-0.18 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $192.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $245.3M | $715.5M |
| 总资产 | $420.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMPLZLAB
| Q4 25 | $192.0M | $689.6M | ||
| Q3 25 | $189.2M | $717.2M | ||
| Q2 25 | $208.1M | $732.2M | ||
| Q1 25 | $209.0M | $757.3M | ||
| Q4 24 | $241.1M | $779.7M | ||
| Q3 24 | $319.9M | $616.1M | ||
| Q2 24 | $318.3M | $630.0M | ||
| Q1 24 | $316.1M | $650.8M |
股东权益AMPLZLAB
| Q4 25 | $245.3M | $715.5M | ||
| Q3 25 | $262.2M | $759.9M | ||
| Q2 25 | $279.5M | $791.7M | ||
| Q1 25 | $289.5M | $810.8M | ||
| Q4 24 | $296.6M | $840.9M | ||
| Q3 24 | $290.0M | $667.7M | ||
| Q2 24 | $287.3M | $704.2M | ||
| Q1 24 | $289.2M | $762.2M |
总资产AMPLZLAB
| Q4 25 | $420.7M | $1.2B | ||
| Q3 25 | $438.1M | $1.2B | ||
| Q2 25 | $456.6M | $1.2B | ||
| Q1 25 | $445.8M | $1.2B | ||
| Q4 24 | $445.9M | $1.2B | ||
| Q3 24 | $445.6M | $985.3M | ||
| Q2 24 | $445.4M | $987.4M | ||
| Q1 24 | $437.9M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $12.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 13.8% | -21.0% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $28.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流AMPLZLAB
| Q4 25 | $12.8M | $-26.0M | ||
| Q3 25 | $5.0M | $-32.0M | ||
| Q2 25 | $20.1M | $-31.0M | ||
| Q1 25 | $-8.0M | $-61.7M | ||
| Q4 24 | $3.2M | $-55.8M | ||
| Q3 24 | $6.2M | $-26.8M | ||
| Q2 24 | $9.2M | $-42.2M | ||
| Q1 24 | $-48.0K | $-90.1M |
自由现金流AMPLZLAB
| Q4 25 | $12.7M | $-26.7M | ||
| Q3 25 | $4.5M | $-35.0M | ||
| Q2 25 | $19.5M | $-33.9M | ||
| Q1 25 | $-8.5M | $-63.2M | ||
| Q4 24 | $2.4M | $-58.4M | ||
| Q3 24 | $6.2M | $-28.2M | ||
| Q2 24 | $8.6M | $-42.9M | ||
| Q1 24 | $-405.0K | $-91.1M |
自由现金流率AMPLZLAB
| Q4 25 | 13.8% | -21.0% | ||
| Q3 25 | 5.1% | -30.4% | ||
| Q2 25 | 23.4% | -31.1% | ||
| Q1 25 | -10.6% | -59.9% | ||
| Q4 24 | 3.1% | -53.8% | ||
| Q3 24 | 8.2% | -27.7% | ||
| Q2 24 | 11.8% | -42.9% | ||
| Q1 24 | -0.6% | -104.5% |
资本支出强度AMPLZLAB
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.5% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 1.0% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.8% | 0.7% | ||
| Q1 24 | 0.5% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPL
| US | $55.8M | 61% |
| International | $35.7M | 39% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
